PHARMAVEST ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.4% 1.9% 1.2% 1.0% 0.9%  
Credit score (0-100)  79 70 82 86 89  
Credit rating  A A A A A  
Credit limit (kDKK)  37.9 1.4 190.4 344.5 569.6  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  1,771 1,159 1,762 1,771 1,975  
EBITDA  1,254 547 1,070 1,080 1,156  
EBIT  1,142 464 992 1,034 1,114  
Pre-tax profit (PTP)  1,071.5 383.8 837.6 879.8 1,287.3  
Net earnings  817.8 281.3 618.0 680.5 1,013.4  
Pre-tax profit without non-rec. items  1,072 384 838 880 1,287  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  231 149 161 19.8 615  
Shareholders equity total  3,643 3,804 4,302 4,857 5,746  
Interest-bearing liabilities  32.9 5.2 12.6 16.3 30.1  
Balance sheet total (assets)  4,319 5,192 5,293 6,042 6,838  

Net Debt  -1,882 -1,912 -2,951 -3,946 -3,438  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,771 1,159 1,762 1,771 1,975  
Gross profit growth  63.2% -34.6% 52.0% 0.5% 11.6%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  4,319 5,192 5,293 6,042 6,838  
Balance sheet change%  15.7% 20.2% 1.9% 14.2% 13.2%  
Added value  1,254.0 546.9 1,069.9 1,112.7 1,156.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -225 -165 -66 -186 553  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  64.4% 40.1% 56.3% 58.4% 56.4%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  26.7% 8.6% 16.4% 18.5% 17.3%  
ROI %  32.4% 10.9% 21.2% 22.8% 24.1%  
ROE %  24.8% 7.6% 15.2% 14.9% 19.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  84.3% 73.3% 81.3% 80.4% 84.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -150.1% -349.6% -275.8% -365.4% -297.3%  
Gearing %  0.9% 0.1% 0.3% 0.3% 0.5%  
Net interest  0 0 0 0 0  
Financing costs %  10.7% 130.6% 277.2% 1,178.8% 27.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  3.9 2.3 4.0 4.2 4.5  
Current Ratio  5.9 3.6 5.2 5.2 5.9  
Cash and cash equivalent  1,915.2 1,917.1 2,963.3 3,961.8 3,468.1  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  3,292.2 3,600.7 3,527.6 3,487.3 3,044.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  1,254 547 1,070 1,113 1,156  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  1,254 547 1,070 1,080 1,156  
EBIT / employee  1,142 464 992 1,034 1,114  
Net earnings / employee  818 281 618 680 1,013